Anna Ljung
Chief Executive Officer chez MOBERG PHARMA AB
Fortune : 986 $ au 31/03/2024
Profil
Anna Ljung currently works at Moberg Pharma AB, as Chief Executive Officer from 2019, Moberg Derma Incentives AB, as Chairman, ADDvise Group AB, as Independent Director from 2022, Saniona AB, as Independent Director from 2018, and Saniona A, as Director.
Ms. Ljung also formerly worked at OncoZenge AB, as Chairman from 2020 to 2023, Advantice Health LLC (New Jersey), as Director, Mpj Otc AB, as Director, Athera Biotechnologies AB, as Chief Financial Officer from 2005 to 2006, and Lipopetide AB, as Chief Financial Officer from 2005 to 2006.
Ms. Ljung received her graduate degree from Stockholm School of Economics.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SANIONA AB
0,00% | 31/12/2022 | 5 471 ( 0,00% ) | 986 $ | 31/03/2024 |
Postes actifs de Anna Ljung
| Sociétés | Poste | Début |
|---|---|---|
| MOBERG PHARMA AB | Chief Executive Officer | 15/05/2019 |
| SANA AB | Director/Board Member | 19/01/2018 |
| ADDVISE GROUP AB | Director/Board Member | 01/01/2022 |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Director/Board Member | - |
| Moberg Derma Incentives AB | Chairman | - |
Anciens postes connus de Anna Ljung
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOZENGE AB | Chairman | 21/08/2023 |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Director of Finance/CFO | 01/01/2006 |
| Lipopetide AB | Director of Finance/CFO | 01/01/2006 |
Advantice Health LLC (New Jersey)
 Advantice Health LLC (New Jersey) Medical DistributorsDistribution Services Advantice Health LLC manufactures and supplies therapeutic medicines and personal products. It is engaged in the marketing, sale and distribution of over-the-counter (OTC) medicines to drug stores, food stores, mass merchandisers, health professionals and international markets. It is best known for podiatrist recommended Kerasal One-Step Exfoliating Moisturizer Therapy. The company was founded in 2004 and is headquartered in Cedar Knolls, NJ. | Director/Board Member | - |
| ░░░ ░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Anna Ljung
| Stockholm School of Economics | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ADDVISE GROUP AB | Distribution Services |
| MOBERG PHARMA AB | Health Technology |
| SANA AB | Health Technology |
| ONCOZENGE AB | Health Technology |
| Entreprise privées | 6 |
|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Advantice Health LLC (New Jersey)
Advantice Health LLC (New Jersey) Medical DistributorsDistribution Services Advantice Health LLC manufactures and supplies therapeutic medicines and personal products. It is engaged in the marketing, sale and distribution of over-the-counter (OTC) medicines to drug stores, food stores, mass merchandisers, health professionals and international markets. It is best known for podiatrist recommended Kerasal One-Step Exfoliating Moisturizer Therapy. The company was founded in 2004 and is headquartered in Cedar Knolls, NJ. | Distribution Services |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Commercial Services |
| Lipopetide AB | |
Mpj Otc AB
 Mpj Otc AB Pharmaceuticals: OtherHealth Technology Part of Moberg Pharma AB, Mpj Otc AB is a private company that manufactures and distributes therapeutic medicines and personal products. | Health Technology |
| Moberg Derma Incentives AB |
